
Human Immunodeficiency Virus Therapeutics Market by Drug Class (Coreceptor Antagonists, Entry & Fusion Inhibitors, Integrase Inhibitors), End-User (Hospitals & Clinics, Specialty Centers), Distribution Channel - Global Forecast 2024-2030
Description
Human Immunodeficiency Virus Therapeutics Market by Drug Class (Coreceptor Antagonists, Entry & Fusion Inhibitors, Integrase Inhibitors), End-User (Hospitals & Clinics, Specialty Centers), Distribution Channel - Global Forecast 2024-2030
The Human Immunodeficiency Virus Therapeutics Market size was estimated at USD 19.34 billion in 2023 and expected to reach USD 20.28 billion in 2024, at a CAGR 4.63% to reach USD 26.55 billion by 2030.
Global Human Immunodeficiency Virus Therapeutics Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Human Immunodeficiency Virus Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Immunodeficiency Virus Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Human Immunodeficiency Virus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., BioNTech SE, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, CytoDyn Inc., Dewpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, ImmunityBio, Inc., Johnson & Johnson Services, Inc., Mylan NV, Pfizer, Inc., Starpharma Holdings Limited, TaiMed Biologics, Inc., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Human Immunodeficiency Virus Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug Class
Coreceptor Antagonists
Entry & Fusion Inhibitors
Integrase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Nucleoside-Analog Reverse Transcriptase Inhibitors
Protease Inhibitors
End-User
Hospitals & Clinics
Specialty Centers
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Human Immunodeficiency Virus Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Immunodeficiency Virus Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Human Immunodeficiency Virus Therapeutics Market?
4. What is the market share of the leading vendors in the Human Immunodeficiency Virus Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Human Immunodeficiency Virus Therapeutics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Human Immunodeficiency Virus Therapeutics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of HIV infections particularly amongst the youth
- 5.1.1.2. Rising awareness about infection and availability of efficient treatments
- 5.1.1.3. Increasing funding and approval of drugs
- 5.1.2. Restraints
- 5.1.2.1. High cost of antiretroviral therapies and rising drug resistance
- 5.1.3. Opportunities
- 5.1.3.1. Collaborative efforts of government and various NGOs
- 5.1.3.2. Technological advancements in point-of-care testing for HIV
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness about the mode of transmission
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Human Immunodeficiency Virus Therapeutics Market, by Drug Class
- 6.1. Introduction
- 6.2. Coreceptor Antagonists
- 6.3. Entry & Fusion Inhibitors
- 6.4. Integrase Inhibitors
- 6.5. Non-Nucleoside Reverse Transcriptase Inhibitors
- 6.6. Nucleoside-Analog Reverse Transcriptase Inhibitors
- 6.7. Protease Inhibitors
- 7. Human Immunodeficiency Virus Therapeutics Market, by End-User
- 7.1. Introduction
- 7.2. Hospitals & Clinics
- 7.3. Specialty Centers
- 8. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Hospital Pharmacies
- 8.3. Online Pharmacies
- 8.4. Retail Pharmacies
- 9. Americas Human Immunodeficiency Virus Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.
- 10. South Korea
- 10.
- 11. Taiwan
- 10.
- 12. Thailand
- 10.
- 13. Vietnam
- 11. Europe, Middle East & Africa Human Immunodeficiency Virus Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.
- 10. Nigeria
- 11.
- 11. Norway
- 11.
- 12. Poland
- 11.
- 13. Qatar
- 11.
- 14. Russia
- 11.
- 15. Saudi Arabia
- 11.
- 16. South Africa
- 11.
- 17. Spain
- 11.
- 18. Sweden
- 11.
- 19. Switzerland
- 11.
- 20. Turkey
- 11.
- 21. United Arab Emirates
- 11.
- 22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. AbbVie, Inc.
- 13.1.2. BioNTech SE
- 13.1.3. Boehringer Ingelheim GmbH
- 13.1.4. Bristol-Myers Squibb Company
- 13.1.5. Cipla Limited
- 13.1.6. CytoDyn Inc.
- 13.1.7. Dewpoint Therapeutics Inc.
- 13.1.8. F. Hoffmann-La Roche Ltd.
- 13.1.9. Genentech, Inc.
- 13.1.
- 10. Gilead Sciences, Inc.
- 13.1.
- 11. GlaxoSmithKline PLC
- 13.1.
- 12. ImmunityBio, Inc.
- 13.1.
- 13. Johnson & Johnson Services, Inc.
- 13.1.
- 14. Mylan NV
- 13.1.
- 15. Pfizer, Inc.
- 13.1.
- 16. Starpharma Holdings Limited
- 13.1.
- 17. TaiMed Biologics, Inc.
- 13.1.
- 18. Teva Pharmaceutical Industries Ltd.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 10. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 12. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.